drugset
drugset / Trial / NCT01646073

Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

NCT01646073 ↗

Phase 3 Completed 425 enrolled AbbVie
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe plaque psoriasis.

Timeline

Start
2012-08
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg —

Indications

psoriasis